ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

Rhea-AI Summary

ProKidney (Nasdaq: PROK), a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), has announced its participation in the H.C. Wainwright 4th Annual Kidney Virtual Conference. The company's management team will engage in a fireside chat on Monday, July 14, 2025, at 1:30 PM ET.

Investors can access the live webcast through the Events section of ProKidney's Investor Relations webpage at www.prokidney.com. One-on-one meetings are available through H.C. Wainwright representatives.

WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the upcoming H.C. Wainwright 4^th Annual Kidney Virtual Conference:

H.C. Wainwright 4th Annual Kidney Virtual Conference
Date:	Monday, July 14, 2025
Time:	1:30pm ET
Format:	Fireside Chat
Webcast:	Link

The live webcast will be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Investors interested in one-on-one meetings should contact their H.C. Wainwright representative.

About ProKidney Corp.
ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT^®), is a first-in-class, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit www.prokidney.com.

Investor Contacts:

ProKidney
Ethan Holdaway
Ethan.Holdaway@prokidney.com

LifeSci Advisors, LLC
Daniel Ferry
Daniel@lifesciadvisors.com

FAQ

When is ProKidney (PROK) presenting at the H.C. Wainwright Kidney Conference 2025?

ProKidney will present at the conference on Monday, July 14, 2025 at 1:30 PM ET in a fireside chat format.

How can investors watch ProKidney's (PROK) presentation at the H.C. Wainwright conference?

Investors can watch the live webcast through the Events section of ProKidney's website at www.prokidney.com under the Investor Relations tab.

What is ProKidney's (PROK) main focus as a company?

ProKidney is a late clinical-stage cellular therapeutics company primarily focused on developing treatments for chronic kidney disease (CKD).

How can investors arrange one-on-one meetings with ProKidney (PROK) management?

Investors interested in one-on-one meetings should contact their H.C. Wainwright representative to arrange a meeting.